Understand the source comparison
Does Tesofensine Help Weight Loss Plateau Research: Type Comparison
Tesofensine 0.5mg Triple monoamine reuptake inhibitor (norepinephrine, dopamine, serotonin). Increases synaptic neurotransmitter availability 10.6% body weight reduction at 24 weeks in plateau-resistant population (Lancet Phase 2b) Heart rate increase 6–8 bpm,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine 0.5mg
- Triple monoamine reuptake inhibitor (norepinephrine, dopamine, serotonin). Increases synaptic neurotransmitter availability
- 10.6% body weight reduction at 24 weeks in plateau-resistant population (Lancet Phase 2b)
- Heart rate increase 6–8 bpm, mild hypertension, dry mouth, insomnia (dose-dependent)
- Phase 2b RCT in 203 obese adults with prior weight loss resistance
- Mechanistically addresses adaptive thermogenesis directly; limited long-term safety data but Phase 2 efficacy in plateau scenarios is robust
- Semaglutide 2.4mg (Wegovy)
- GLP-1 receptor agonist. Slows gastric emptying, enhances satiety signalling, reduces ghrelin rebound
- 14.9% body weight reduction at 68 weeks; velocity slows significantly after week 20 (STEP-1 trial)
- Nausea 44%, vomiting 24%, diarrhoea 30% during titration; pancreatitis risk <1%
- Multiple Phase 3 RCTs; FDA-approved for chronic weight management
- Highly effective for initial weight loss but doesn't reverse neuroendocrine adaptations; plateaus common after 20–24 weeks
- Tirzepatide 15mg (Zepbound)
- Dual GIP/GLP-1 receptor agonist. Combines incretin effects with enhanced insulin sensitivity
- 20.9% body weight reduction at 72 weeks (SURMOUNT-1); similar plateau pattern to semaglutide after 6 months
- GI side effects 25–50%; lower nausea rate than semaglutide but higher diarrhoea incidence
- Phase 3 RCT in 2,539 adults with obesity; FDA-approved 2023
- Superior to semaglutide in head-to-head trials but mechanism still incretin-based; doesn't target sympathetic tone suppression
- Phentermine/Topiramate ER (Qsymia)
- Sympathomimetic amine (norepinephrine release) + GABA modulator (reduces reward-driven eating)
- 9.3% body weight reduction at 56 weeks; efficacy maintained longer than monotherapy phentermine
- Elevated heart rate, paresthesia, constipation, cognitive effects (word-finding difficulty)
- Phase 3 trials; FDA-approved 2012 for chronic weight management
- Addresses both appetite and energy expenditure but cardiovascular contraindications limit use; not studied specifically in plateau populations
- Dietary Intervention Alone
- Caloric restriction without pharmacological intervention
- Initial 5–10% reduction typical; 80% plateau by 12–16 weeks due to adaptive thermogenesis
- None (behavioral intervention)
- Extensive observational data; sustained weight loss rare without adjunctive therapy
- Plateaus are biologically inevitable once metabolic adaptation equals caloric deficit; pharmacological intervention required to override